$SER News

BTIG Reiterates Buy on Serina Therapeutics, Maintains $8 Price Target

Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress"

Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

BTIG Reiterates Buy on Serina Therapeutics, Maintains $8 Price Target

Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2

Serina Therapeutics Receives Recommendation From Independent Safety Monitoring Committee To Continue Its Phase 1b Registrational Trial Of SER-252 To Cohort 2

Serina Therapeutics Files Prospectus Related To The Offer And Sale Of Up To 12,500,000 Shares Of Common Stock By Roth Principal Investments

Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Serina Therapeutics Q2 EPS $(0.55) Misses $(0.47) Estimate, Sales $130.000K, Same YoY

Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease

Serina Therapeutics Completes Enrollment And Dosing In Cohort 1 Of Ongoing Phase 1b Registrational Clinical Trial Evaluating SER-252 In Patients With Advanced Parkinson’s Disease

Serina Therapeutics Appoints Farrell Simon to its Board of Directors

Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease

Serina Therapeutics Completes Sentinel Dosing In Group 1 Of Its Phase 1b Study Of SER-252 To Treat Parkinson's Disease

BTIG Initiates Coverage On Serina Therapeutics with Buy Rating, Announces Price Target of $8

Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program

Gannet BioChem To Support Development Activities For SER-252, Serina Therapeutics' Investigational Therapy For Advanced Parkinson's Disease

Serina Therapeutics Files Prospectus For Offering 16.45M Common Shares On Behalf Of Selling Stockholders

Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates